Clinical Perspectives and Targeted Therapies in Apoptosis

Drug Discovery, Drug Delivery, and Disease Prevention

Häftad, Engelska, 2020

1 926 kr

Beställningsvara. Skickas inom 10-15 vardagar. Fri frakt över 249 kr.

Beskrivning

Clinical Perspectives and Targeted Therapies in Apoptosis: Drug Discovery, Drug Delivery, and Disease Prevention provides comprehensive coverage, from basic cell biology, to modern assessment techniques for apoptosis in all major disease areas. Chapters provide an introduction to the fundamentals of cell biology, biochemical mechanisms, and the pathophysiological consequences of apoptosis. In addition, the book covers the tools and techniques used to quantify apoptosis and the significance of apoptosis in drug discovery, drug delivery, and its applications in disease prevention. Finally, the book provides a comprehensive compilation of the apoptosis targeting drugs that recently underwent clinical trials.

This combination of fundamentals, along with applications in drug discovery, drug delivery, and clinical research make this book a useful resource for those in both academia and industry who are engaged in pharmaceutical, biomedical and biotechnology research.

Offers standard and innovative therapeutic approaches to modulate apoptosis in clinical interventions, such as cardiovascular diseases, immune disorders, cancer chemotherapy and neurological ailments
Covers cutting-edge laboratory techniques and traditional protocols to determine apoptosis, both in vitro and in vivo
Examines clinical study reports of new drug moieties that are explored for various pathological conditions associated with apoptosis

Produktinformation

Utgivningsdatum:2020-10-15
Mått:191 x 235 x 48 mm
Vikt:1 000 g
Format:Häftad
Språk:Engelska
Antal sidor:432
Förlag:Elsevier Science
ISBN:9780128157626

Utforska kategorier

Farmakologi inom Medicin

Mer om författaren

Dr. Rupinder K Sodhi’s core areas of research cover different segments of neuropharmacology like cognition, dementia and Alzheimer’s disease. Central to her research activities involves evaluation of the potential of new chemical entities using advanced in vitro and in vivo tools and techniques. More over her expertise is in the field of neurodegenerative and neuropsychiatric disorders like Alzheimer, depression and also in diabetes and related complications such as neuropathic pain, nephropathy pain and inflammation aiming to deconvolute the novel target sites for drug discovery and development. Currently she is active in evaluating the therapeutic efficacy of controlled and targeted drug delivery systems such as nanomedicine in collaboration with pharmaceutics department. Dr. Jitender Madan serves as Associate Professor in the Department of Pharmaceutics at NIPER Hyderabad, where he integrates research leadership with graduate-level teaching. He holds a B.Pharmacy from Nagpur University, an M.Pharmacy in Pharmaceutical Biotechnology from Dr. Hari Singh Gour University, and a PhD in Pharmaceutical Sciences from Bundelkhand University; he pursued a postdoctoral fellowship at Georgia State University. He has built a substantial research program in pharmaceutical sciences, mentoring many M. Pharmacy and PhD scholars and contributing to pharmaceutical product development. His leadership has spanned industry and government-funded projects. His scholarly portfolio includes extensive publication in international journals, numerous book chapters, and multiple granted patents pertaining to innovative delivery systems for topical, oral, and intravaginal therapies. His work has earned broad recognition in global rankings within pharmacology and pharmacy.

Innehållsförteckning

1. Introduction to Cell Biology2. Physiology of Cellular Demise3. Molecular Pathways of Apoptotic Cell Death4. Apoptosis: Warrior or Opponent5. Protocols in apoptosis identification and affirmation6. Modulating apoptosis in cancer 7. Cardiovascular diseases8. Recent approaches to target apoptosis in neurological disorders9. Autoimmune diseases and apoptosis: targets, challenges and innovations10. Clinical trials of promising apoptosis modulating drugs